BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29699924)

  • 1. Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
    Liu X; Chen P; Li X; Ba M; Jiao X; Guo Y; Xie P
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1699-1703. PubMed ID: 29699924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives.
    Venkatachalam TK; Mao C; Uckun FM
    Biochem Pharmacol; 2004 May; 67(10):1933-46. PubMed ID: 15130770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
    Wei L; Wang HL; Huang L; Chen CH; Morris-Natschke SL; Lee KH; Xie L
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2788-2792. PubMed ID: 28465101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
    Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
    J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
    Meng Q; Chen X; Kang D; Huang B; Li W; Zhan P; Daelemans D; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2016 Jun; 115():53-62. PubMed ID: 26994843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.
    Venkatachalam TK; Mao C; Uckun FM
    Bioorg Med Chem; 2004 Aug; 12(15):4275-84. PubMed ID: 15246104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.
    O'Meara JA; Yoakim C; Bonneau PR; Bös M; Cordingley MG; Déziel R; Doyon L; Duan J; Garneau M; Guse I; Landry S; Malenfant E; Naud J; Ogilvie WW; Thavonekham B; Simoneau B
    J Med Chem; 2005 Aug; 48(17):5580-8. PubMed ID: 16107158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Viira B; Selyutina A; García-Sosa AT; Karonen M; Sinkkonen J; Merits A; Maran U
    Bioorg Med Chem; 2016 Jun; 24(11):2519-2529. PubMed ID: 27108399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
    Li X; Lu X; Chen W; Liu H; Zhan P; Pannecouque C; Balzarini J; De Clercq E; Liu X
    Bioorg Med Chem; 2014 Oct; 22(19):5290-7. PubMed ID: 25150090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
    Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
    Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
    Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
    J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
    Tang G; Kertesz DJ; Yang M; Lin X; Wang Z; Li W; Qiu Z; Chen J; Mei J; Chen L; Mirzadegan T; Harris SF; Villaseñor AG; Fretland J; Fitch WL; Hang JQ; Heilek G; Klumpp K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6020-3. PubMed ID: 20829038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
    Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.